2025 JPAD

/in , , , , , /by

2025 JPAD:

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer’s disease

2025 JPAD

/in , , , /by

2025 JPAD:

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

 

2024 AAIC Poster

/in , , , , , /by

2024 AAIC Poster:

INTERCEPT-AD: Understanding the Patient Experience and Expectations for Treatment Through Qualitative Interviews Among Trial Participants with Early Alzheimer’s Disease
and Their Study Partners

2024 AAIC Poster

/in , , , , , , /by

2024 AAIC Poster:

Sabirnetug (ACU193) Lowers CSF Levels of Synaptic Biomarkers in INTERCEPT-AD Phase 1 Study in Early AD

2024 AAIC Poster

/in , , , , , , /by

2024 AAIC Poster:

INTERCEPT-AD: Development and Qualification of a Highly Sensitive Immunoassay Detecting Total Sabirnetug (ACU193) in Human CSF

2024 AAIC Poster

/in , , , , , /by

2024 AAIC Poster: 

INTERCEPT-AD: A Gender Analysis of the Phase 1 Experience Among Trial Participants with Early Alzheimer’s Disease and Their Study Partners

2022 JPAD Article

/in , , , , /by

2022 Journal of Prevention of Alzheimer’s Disease:

 

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

2023 CTAD Poster

/in , , , , , /by

2023 CTAD Poster:

Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.

2024 ADPD Presentation

/in , , , , /by

2024 ADPD Presentation:

Sabirnetug (ACU193) Lowers CSF Neurogranin & pTau181 Levels in INTERCEPT-AD Study in Early AD.

2024 ADPD Poster

/in , , , , , /by
2024 ADPD Poster:

 

Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring Sabirnetug (ACU193)-Amyloid Βeta Oligomer Complexes in Human CSF.